COMMUNIQUÉS West-GlobeNewswire

NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
21/05/2024
CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Leisure Care Creates More Connected Lives for Residents with Nationwide Rollout of Rendever
21/05/2024
The VR company and senior living operator are taking their four-year partnership to the next level with immersive virtual reality experiences for residents in dozens of Leisure Care communities BOSTON, May 21, 2024 ( [...]
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
21/05/2024
Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application CTx-1301 Could Benefit >60% of ADHD Patients Currently Using Immediate-Release Booster Doses Advancing Discussions with [...]
Alpha Tau to Present at the Jefferies Global Healthcare Conference
21/05/2024
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that [...]
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
21/05/2024
BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today [...]
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
21/05/2024
Data presented at the 14 th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV ® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sales of $5 [...]
Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting
21/05/2024
Presentations Will Address Phase 2 Trial Success With Lead Asset KET01 And Comparative Study With Intranasal SPRAVATO® MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint [...]
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
21/05/2024
May 21, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) [...]
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
21/05/2024
Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low [...]
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
21/05/2024
Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on [...]
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
21/05/2024
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by [...]
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
21/05/2024
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including [...]
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
21/05/2024
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21/05/2024
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the [...]
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21/05/2024
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the [...]
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
21/05/2024
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that Laurence de Moerlooze will leave her position as Executive Vice President and Chief Medical Officer in the Company to pursue new [...]
Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women
21/05/2024
GAITHERSBURG, MD, May 21, 2024 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“ Amplexd ” or the “ Company ”), a clinical stage patient-scientist-led biotech company specializing in accessible treatments for human [...]
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
21/05/2024
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program
21/05/2024
Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital and existing investors aMoon Fund and Blackstone Multi-Asset Investing, among [...]

Pages